Zamioculcas zamiifolia, an unusually drought resistant medicinal plant native to tropical east Africa and subtropical southeast Africa, including the countries Kenya, Malawi, Mozambique, South-Africa, Tanzania and Zimbabwe, is described as a living fossil which may have evolved as early as 42 million years ago. It belongs to the notoriously toxic family Araceae giving it, through association, a reputation for being toxic; despite little or no systematic evidence exists to support this claim. As an ancient plant it has sustained substantial climate changes and attacks from millions of generations of pathogenic microorganisms, which encouraged search for novel natural products from this source. Seven natural products have been characterized from leaves and petioles of Z. zamiifolia, including the novel main compound of the leaves, apigenin 6-C-(6″-(3-hydroxy-3-methyl-glutaroyl)-ß-glucopyranoside). The structure determinations were based on extensive use of 2D NMR spectroscopic techniques and high-resolution mass spectrometry. Initial toxicological experiment on extracts from Z. zamiifolia using brine shrimp lethality assay did not indicate lethality to the shrimps providing disproving evidence for the assumption of Z. zamiifolia's toxic character.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.fitote.2015.09.011 | DOI Listing |
Cytotherapy
December 2024
Department of Medicine, Kuopio University Hospital, Kuopio, Finland. Electronic address:
The amount of CD34 cells has been for decades the most important marker of autologous graft quality, but other graft cells, including various lymphocyte subsets, have gained some interest. This review attempts to summarize what is known about autograft cellular composition regarding post-transplant outcomes. The amount of CD34 cells in the graft is associated with tempo of platelet recovery.
View Article and Find Full Text PDFEnviron Sci Pollut Res Int
January 2025
CPRAC Research Center, Centre de Recherche Scientifique et Technique en Analyses Physico-Chimiques, Bou-Ismail CP, Tipaza, 42004, Algeria.
The aim of the present work is to investigate the photocatalytic degradation of propyl paraben (propyl para-hydroxybenzoate, PrP) using CuO-ZnO-NPs photocatalyst followed by the identification of the oxidation by-products. The CuO-ZnO-NPs material, synthesized using a green chemistry approach, was used as a photocatalyst for the removal of PrP. The nanoparticles were characterized by XRD, XRF, diffuse reflectance spectroscopy, ATG/DTG, FTIR, SEM-EDX, BET and FRX techniques.
View Article and Find Full Text PDFNat Prod Bioprospect
January 2025
Consejo Nacional de Investigaciones Científicas y Técnicas, Suipacha 531, S2002LRK, Rosario, Argentina.
Chemically engineered extracts represent a promising source of new bioactive semi-synthetic molecules. Prepared through direct derivatization of natural extracts, they can include constituents enriched with elements and sub-structures that are less common in natural products compared to drugs. Fourteen such extracts were prepared through sequential reactions with hydrazine and a fluorinating reagent, and their α-glucosidase inhibition properties were compared.
View Article and Find Full Text PDFSci Rep
January 2025
Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, College of Food Science and Engineering, Inner Mongolia Agricultural University, Hohhot, 010018, China.
Aflatoxin M1 (AFM1) is known to be carcinogenic, mutagenic, and teratogenic and poses a serious threat to food safety and human health, which makes its surveillance critical. In this study, an indirect competitive ELISA (icELISA) based on a nanobody (Nb M4) was developed for the sensitive and rapid detection of AFM1 in dairy products. In our previous work, Nb M4 was screened from a Bactrian-camel-immunized phage-displayed library.
View Article and Find Full Text PDFJ Transl Med
January 2025
Evvivax Biotech, Via Castel Romano 100, 00128, Rome, Italy.
In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. Recently, the therapeutic potential of this therapy has also been demonstrated in non-tumoral diseases. Currently, the manufacturing process to produce clinical-grade CAR-T cells is complex, time-consuming, and highly expensive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!